Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Mar 19, 2023 1:29pm
200 Views
Post# 35347641

RE:RE:About the addition of up to 9 CSS ...

RE:RE:About the addition of up to 9 CSS ...Hi wildbird1 - Yes, Theralase has so much research waiting in the wings. They just don't have the resources to take advantage of it.

GBM and NSCLC treatments using systemically delivered and X-ray activated Rutherrin should be next up. If systemic instillation and X-ray activation goes well, there is the potential for treating many other forms of cancer. Then there's all the melanoma and breast cancer research Dr. McFarland has been doing in recent years. And also her successes  with low oxygen enviroment PSs which do not rely on ROS production. Plus, if all goes well, there's the covid vaccine phase 1 for 2024 and then other anti-viral and anti-bacterial treatments.

Theralase just needs the money to get the ball rolling.
<< Previous
Bullboard Posts
Next >>